Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition

J Drugs Dermatol. 2015 Mar;14(3):244-53.


Advances in the understanding of the pathogenesis of psoriasis have led to the development of biologic agents that target T cells and cytokines that play a specific role in the underlying inflammation associated with psoriasis (eg, tumor necrosis factor-α inhibitors, interleukin [IL]-12/23 inhibitors). In this review, evidence for the central role of IL-17 in the pathophysiology of psoriasis is presented, along with available clinical trial data on the selective IL-17 inhibitors in development. Three biologic agents that target IL-17 are currently in clinical development: secukinumab, ixekizumab, and brodalumab. Clinical studies to date suggest a favorable safety profile and the potential for better efficacy over the previous generation of agents, with Psoriasis Area Severity Index 75 response rates of up to 80% or greater. Fully published results of phase III studies of these agents are eagerly awaited.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Biological Products / pharmacology
  • Biological Products / therapeutic use*
  • Disease Management*
  • Humans
  • Interleukin-17 / antagonists & inhibitors*
  • Interleukin-17 / immunology
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / immunology


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Interleukin-17
  • brodalumab